Evidence map›Paper›PMID 41469925›Full record

SynthesisItalian journal of pediatrics2025

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis.

Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S Jibril, Hebatullah Abdulazeem, Mohammed Alsabri

Abstract readMeta-AnalysisSystematic ReviewReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed Saad SayedFaculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt.
Mena Ayman ElgendyFaculty of Medicine, Misr University For Science and Technology, Giza, Egypt.
Nada GamilFaculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, 33516, Egypt.
Hossam Hassan AbdullahFaculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt.
Alaa AlhwaryDepartment of Microbiology and Immunology, Kafr Elsheikh University, Kafr Elsheikh, 33516, Egypt.
Rahma Abdulfattah IbrahimFaculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, 33516, Egypt.
Sama Hesham SamirFaculty of Medicine, Helwan University, Helwan, Egypt.
Nada S JibrilFaculty of Medicine, Menoufia University, Menoufia, Egypt.
Hebatullah Abdulazeem *Chair of Epidemiology, TUM School of Medicine and Health, Technical University of Munich, 80809, Munich, Germany.
Mohammed Alsabri *Emergency Department, Althawara Modern General Hospital, Sanaa, Yemen. alsabri5000@gmail.com.ORCID http://orcid.org/0000-0002-1410-7680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants. Clinical trials have shown that a single dose of nirsevimab can prevent this infection and its related complications. We systematically searched PubMed, Embase, Web of Science (WOS), Scopus, and Cochrane Central on 25 November 2024 and updated on 18 April 2025, without automated filters or language restrictions. Studies reported the outcomes after nirsevimab in infants were retrieved. A random effects model was applied for analysis. A total of 425,362 infants were pooled from 26 studies (6 randomized controlled trials and 20 observational cohorts studies). The immunization with nirsevimab reduced the incidence of RSV-LRTIs by 63% (risk ratio [RR]: 0.37; 95% CI [0.29; 0.47], p-value < 0.001, I

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus InfectionsHospitalizationHumansInfantInfant, NewbornTreatment OutcomeAntibodies, Monoclonal, HumanizedAntiviral AgentsHospitalizationInfantsMeta-analysisNirsevimabRespiratory syncytial virusTime-to-event analysis

Identifiers

PMID41469925
PMCPMC12860166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.